Etoposide kinetics in patients with obstructive jaundice

K. R. Hande, S. N. Wolff, F. A. Greco, J. D. Hainsworth, G. Reed, D. H. Johnson

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The kinetics and urinary excretion of etoposide and etoposide glucuronide were determined in 11 patients with obstructive jaundice (bilirubin > 2.0 mg/dL) and in 23 patients with normal renal and hepatic function. Mean (± SE) measurements of clearance (24.5 ± 2.06 v 26.5 ± 2.05 mL/min/m2), half-life (5.7 ± 0.5 v 6.4 ± 0.5 hours), and volume of distribution (12.4 ± 1.1 v 13.7 ± 1.6 L/m2) were not significantly different in patients with jaundice when compared with controls. Similarly, etoposide kinetics in three patients determined during a period of hyperbilirubinemia were not different from measurements made in the same patients following resolution of their obstructive jaundice. In patients with jaundice, 46% of an administered etoposide dose was excreted in the urine as etoposide compared with 35% in controls (P = .15). Urinary excretion of etoposide glucuronide accounted for 29% of an administered etoposide dose in control patients and 15% in those with hepatic obstruction (P = .03). Biliary etoposide excretion measured in four patients with T-tubes was insignificant (<2.0% of an administered dose). The calculated renal clearance of etoposide was 11.5 mL/min/m2 in patients with jaundice and 10.4 mL/min/m2 in controls (P = .053). Respective metabolic clearance was 4.9 ± 6.9 mL/min/m2 in these two study groups (P = .13). Although hepatic metabolism of etoposide may be slightly decreased in patients with obstructive jaundice, a modest increase in renal etoposide excretion appears to compensate for this change, so that total clearance is similar in the patients with jaundice when compared with controls. No etoposide dose reductions appear to be needed in treating patients with obstructive jaundice who have normal renal function.

Original languageEnglish (US)
Pages (from-to)1101-1107
Number of pages7
JournalJournal of Clinical Oncology
Volume8
Issue number6
DOIs
StatePublished - 1990

Fingerprint

Obstructive Jaundice
Etoposide
Jaundice
Kidney
Liver
Hyperbilirubinemia
Bilirubin
Half-Life
Urine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hande, K. R., Wolff, S. N., Greco, F. A., Hainsworth, J. D., Reed, G., & Johnson, D. H. (1990). Etoposide kinetics in patients with obstructive jaundice. Journal of Clinical Oncology, 8(6), 1101-1107. https://doi.org/10.1200/JCO.1990.8.6.1101

Etoposide kinetics in patients with obstructive jaundice. / Hande, K. R.; Wolff, S. N.; Greco, F. A.; Hainsworth, J. D.; Reed, G.; Johnson, D. H.

In: Journal of Clinical Oncology, Vol. 8, No. 6, 1990, p. 1101-1107.

Research output: Contribution to journalArticle

Hande, KR, Wolff, SN, Greco, FA, Hainsworth, JD, Reed, G & Johnson, DH 1990, 'Etoposide kinetics in patients with obstructive jaundice', Journal of Clinical Oncology, vol. 8, no. 6, pp. 1101-1107. https://doi.org/10.1200/JCO.1990.8.6.1101
Hande, K. R. ; Wolff, S. N. ; Greco, F. A. ; Hainsworth, J. D. ; Reed, G. ; Johnson, D. H. / Etoposide kinetics in patients with obstructive jaundice. In: Journal of Clinical Oncology. 1990 ; Vol. 8, No. 6. pp. 1101-1107.
@article{f08a2eb9bd094a3ba553de99f9bc8f8e,
title = "Etoposide kinetics in patients with obstructive jaundice",
abstract = "The kinetics and urinary excretion of etoposide and etoposide glucuronide were determined in 11 patients with obstructive jaundice (bilirubin > 2.0 mg/dL) and in 23 patients with normal renal and hepatic function. Mean (± SE) measurements of clearance (24.5 ± 2.06 v 26.5 ± 2.05 mL/min/m2), half-life (5.7 ± 0.5 v 6.4 ± 0.5 hours), and volume of distribution (12.4 ± 1.1 v 13.7 ± 1.6 L/m2) were not significantly different in patients with jaundice when compared with controls. Similarly, etoposide kinetics in three patients determined during a period of hyperbilirubinemia were not different from measurements made in the same patients following resolution of their obstructive jaundice. In patients with jaundice, 46{\%} of an administered etoposide dose was excreted in the urine as etoposide compared with 35{\%} in controls (P = .15). Urinary excretion of etoposide glucuronide accounted for 29{\%} of an administered etoposide dose in control patients and 15{\%} in those with hepatic obstruction (P = .03). Biliary etoposide excretion measured in four patients with T-tubes was insignificant (<2.0{\%} of an administered dose). The calculated renal clearance of etoposide was 11.5 mL/min/m2 in patients with jaundice and 10.4 mL/min/m2 in controls (P = .053). Respective metabolic clearance was 4.9 ± 6.9 mL/min/m2 in these two study groups (P = .13). Although hepatic metabolism of etoposide may be slightly decreased in patients with obstructive jaundice, a modest increase in renal etoposide excretion appears to compensate for this change, so that total clearance is similar in the patients with jaundice when compared with controls. No etoposide dose reductions appear to be needed in treating patients with obstructive jaundice who have normal renal function.",
author = "Hande, {K. R.} and Wolff, {S. N.} and Greco, {F. A.} and Hainsworth, {J. D.} and G. Reed and Johnson, {D. H.}",
year = "1990",
doi = "10.1200/JCO.1990.8.6.1101",
language = "English (US)",
volume = "8",
pages = "1101--1107",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Etoposide kinetics in patients with obstructive jaundice

AU - Hande, K. R.

AU - Wolff, S. N.

AU - Greco, F. A.

AU - Hainsworth, J. D.

AU - Reed, G.

AU - Johnson, D. H.

PY - 1990

Y1 - 1990

N2 - The kinetics and urinary excretion of etoposide and etoposide glucuronide were determined in 11 patients with obstructive jaundice (bilirubin > 2.0 mg/dL) and in 23 patients with normal renal and hepatic function. Mean (± SE) measurements of clearance (24.5 ± 2.06 v 26.5 ± 2.05 mL/min/m2), half-life (5.7 ± 0.5 v 6.4 ± 0.5 hours), and volume of distribution (12.4 ± 1.1 v 13.7 ± 1.6 L/m2) were not significantly different in patients with jaundice when compared with controls. Similarly, etoposide kinetics in three patients determined during a period of hyperbilirubinemia were not different from measurements made in the same patients following resolution of their obstructive jaundice. In patients with jaundice, 46% of an administered etoposide dose was excreted in the urine as etoposide compared with 35% in controls (P = .15). Urinary excretion of etoposide glucuronide accounted for 29% of an administered etoposide dose in control patients and 15% in those with hepatic obstruction (P = .03). Biliary etoposide excretion measured in four patients with T-tubes was insignificant (<2.0% of an administered dose). The calculated renal clearance of etoposide was 11.5 mL/min/m2 in patients with jaundice and 10.4 mL/min/m2 in controls (P = .053). Respective metabolic clearance was 4.9 ± 6.9 mL/min/m2 in these two study groups (P = .13). Although hepatic metabolism of etoposide may be slightly decreased in patients with obstructive jaundice, a modest increase in renal etoposide excretion appears to compensate for this change, so that total clearance is similar in the patients with jaundice when compared with controls. No etoposide dose reductions appear to be needed in treating patients with obstructive jaundice who have normal renal function.

AB - The kinetics and urinary excretion of etoposide and etoposide glucuronide were determined in 11 patients with obstructive jaundice (bilirubin > 2.0 mg/dL) and in 23 patients with normal renal and hepatic function. Mean (± SE) measurements of clearance (24.5 ± 2.06 v 26.5 ± 2.05 mL/min/m2), half-life (5.7 ± 0.5 v 6.4 ± 0.5 hours), and volume of distribution (12.4 ± 1.1 v 13.7 ± 1.6 L/m2) were not significantly different in patients with jaundice when compared with controls. Similarly, etoposide kinetics in three patients determined during a period of hyperbilirubinemia were not different from measurements made in the same patients following resolution of their obstructive jaundice. In patients with jaundice, 46% of an administered etoposide dose was excreted in the urine as etoposide compared with 35% in controls (P = .15). Urinary excretion of etoposide glucuronide accounted for 29% of an administered etoposide dose in control patients and 15% in those with hepatic obstruction (P = .03). Biliary etoposide excretion measured in four patients with T-tubes was insignificant (<2.0% of an administered dose). The calculated renal clearance of etoposide was 11.5 mL/min/m2 in patients with jaundice and 10.4 mL/min/m2 in controls (P = .053). Respective metabolic clearance was 4.9 ± 6.9 mL/min/m2 in these two study groups (P = .13). Although hepatic metabolism of etoposide may be slightly decreased in patients with obstructive jaundice, a modest increase in renal etoposide excretion appears to compensate for this change, so that total clearance is similar in the patients with jaundice when compared with controls. No etoposide dose reductions appear to be needed in treating patients with obstructive jaundice who have normal renal function.

UR - http://www.scopus.com/inward/record.url?scp=0025328966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025328966&partnerID=8YFLogxK

U2 - 10.1200/JCO.1990.8.6.1101

DO - 10.1200/JCO.1990.8.6.1101

M3 - Article

C2 - 2348225

AN - SCOPUS:0025328966

VL - 8

SP - 1101

EP - 1107

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -